Conestoga Capital Advisors released its third-quarter 2025 investor letter, noting equity markets hit new highs. Their Mid Cap Composite returned -3.2% net-of-fees, underperforming the Russell Midcap Growth Index’s 2.8% gain. IDEXX Laboratories, Inc. (NASDAQ: IDXX) was highlighted, with a one-month return of -1.74% and a market cap of $50.97 billion.

IDEXX Laboratories Inc. (NASDAQ: IDXX) saw strong earnings growth in Q3 2025, leading the industry in veterinary diagnostics and testing. Its stock closed at $637.13 per share on October 21, 2025, with a one-year gain of 38.06%. Conestoga Capital Advisors praised IDEXX’s organic revenue growth and premium instrument adoption in their investor letter.

Despite IDEXX Laboratories Inc.’s (NASDAQ: IDXX) revenue growth and position as a market leader, it’s not a top pick among hedge funds. While 48 hedge fund portfolios held the stock in Q2 2025, certain AI stocks are seen as offering more upside potential with less downside risk. Consider exploring other investment opportunities for better returns.

Read more at Yahoo Finance: IDEXX Laboratories (IDXX) Surged Following Strong Earnings